THE TRENDLINES GROUP LTD.
(Incorporated in Israel)
(Company Registration No. 513970947)

Incorporation of Portfolio Companies which are considered Subsidiaries

---

The board of directors (the "**Board**") of The Trendlines Group Ltd. (the "**Company**" and together with its subsidiaries and associated companies, the "**Group**") wishes to announce that the following portfolio companies, which are considered Subsidiaries[1], have recently been incorporated by the Group:

Name of Portfolio Company	Country of Incorporation	Principal Activity	Issued and Paid-up capital	Percentage of Ownership by Trendlines Medical Singapore Pte. Ltd. and the Group
OccuTrack Medical Solutions Pte. Ltd.	Singapore	OccuTrack Medical Solutions Pte. Ltd. is focused on developing solutions to monitor deteriorating visual acuity conditions such as Aged Macular Degeneration. The technology comes from previous research collaboration between The National Healthcare Group eye institute and the Agency for Science, Technology and Research in Singapore ("A*STAR").	S$1	100%
NICE Surgical Solutions Pte. Ltd.	Singapore	NICE Surgical Solutions Pte. Ltd. is focused on developing tools to allow for easier and faster fully intracorporeal left side colorectal anastomosis surgery. The concept comes from a surgeon based in the USA and the new start-up will be developing the concept in Singapore.	S$1	100%

[1] As such term is defined under the Companies Act (Chapter 50) of Singapore.

The incorporation of the above-mentioned subsidiaries is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ended 31 December 2019.

None of the Company's Directors, substantial shareholders and/or any of their respective associates has any interest, direct or indirect (other than through their shareholdings in the Company), in the above-mentioned portfolio companies.

BY ORDER OF THE BOARD
THE TRENDLINES GROUP LTD.

Haim Brosh,
Joint Company Secretary

6 January 2020

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).